Xenacare Holdings Inc.(fka XCHO)

[stervc]

XCHO Potential Revenues Comparison…

Ultram (tramadol hydrochloride) and other pain relievers have sales totaling in the billions of dollars annually on a regular basis. Celebrex, Vioxx, and Ultram are drugs used to treat chronic pain. Celebrex, Vioxx, and Ultram have made multi-billions of dollars for Pfizer, Merk, and Johnson&Johnson respectively.

In the 2008 Pharma Report below, Celebrex reported to have made $2.29 billion alone for Pfizer which is the #1 Pharmaceutical Company in the US:
http://www.imshealth.com/imshealth/05_01_08MM&MPharmaTopDiana.pdf

The clinical study below conducted by the American Society of Clinical Oncology (ASCO) confirmed that Cobroxin, for chronic pain, is better than Ultram (tramadol hydrochloride) and would be better than Celebrex and Vioxx because of not having the side effects reported from Celebrex and Vioxx:
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=16&abstractID=1762

XCHO is an OTCBB stock that regularly files with the SEC. There are no CDs, S-8s, or any other forms of toxic financing/dilution.

Logically thinking, NEPH trades on the OTCBB and was initially at .025 about three or four months ago. Then NEPH stabilized in the .075 to .14 per share range. Then NEPH stabilized in the .32 to .62 per share range. Then it stabilized over the $1.00+ per share range. Now, this past Friday, NEPH is at $1.71 per share. NEPH has a similar share structure as XCHO, but XCHO has more potential because their sales are not just to hospitals but to all consumers and major companies.

XCHO has the clinical data and science to justify why it is fair to believe that XCHO should at the very least mirror similar trading patterns of NEPH now that Cobroxin is beginning to be marketed by the XCHO. As the word gets out and the market is made known that XCHO has the ”exclusive” license to market and distribute Cobroxin, an FDA Approved over the counter treatment for chronic pain, then higher levels should be obtained to better mirror its true actual and potential valuations.

v/r
Sterling